Cardiovascular events in users of sildenafil: results from first phase of prescription event monitoring in England
about
Cardiovascular events in users of sildenafil. Paper does not provide any reassurance.Erectile dysfunction and cardiovascular risk factors.Sildenafil citrate use and the incidence of nonarteritic anterior ischemic optic neuropathy.Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases.Influence of a single dose of 20 mg tadalafil, a phosphodiesterase 5 inhibitor, on ambulatory blood pressure in subjects with hypertension.Erectile dysfunction in heart disease patients.Erectile dysfunction in patients with coronary artery disease.Pharmacotherapy of erectile dysfunction: focus on cardiovascular safety.Effect of sildenafil citrate on the cardiovascular system.Chronic sildenafil in men with diabetes and erectile dysfunction.Sexual activity and ischemic heart disease.Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): How do they work?Erectile dysfunction and its management in patients with diabetes mellitus.Incidence of erectile dysfunction and characteristics of patients before and after the introduction of sildenafil in the United Kingdom: cross sectional study with comparison patients.An unusual adverse effect of sildenafil citrate: acute myocardial infarction in a nitrate-free patient.Clinical update on sildenafil citrate.Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling.A case of erectile dysfunction and risk factors for coronary artery disease.Sex, the heart, and heart failure.
P2860
Q28344616-30B09819-DE56-4C82-8E6E-207D565F6BE9Q34342578-B292FF0C-B97C-4609-BE89-0EF644A81C68Q34569289-324AB82A-6162-46FB-878A-2A5B9EEDDB6BQ35500693-D0D7D126-5468-41F6-A0CB-173814E11BE5Q35827790-34A30A33-3616-4DD1-A87D-CDC19332CDB6Q35924324-E68F8275-0F1B-49E2-9818-8D8AF9424842Q36053660-DFF8A7B4-6CCD-4232-8638-E173FA519208Q36150572-B46218E2-EB7C-4AFF-BD83-D6C3AD2F7CD6Q36247128-68648A3C-7E29-4AC7-8670-A3723DBBE54FQ36835843-BAC8B3F2-83C3-4665-A95B-8519578E143DQ38177225-DE1E5D58-D05B-445F-B545-74A86356571EQ38542767-BDC9477A-C59A-45D4-855D-0EC61910B591Q38615555-D8736E7B-4BB5-4409-BB27-47B3D2BBD70CQ39732295-43345700-CBD6-4E77-80D8-DE0C9AA262B0Q42078895-203C3DA3-E92F-4C41-8A9D-FEFE6989C163Q42780422-DAA0EEC4-1499-467A-BCC9-6850D7556CBBQ44907848-E10B81F6-8C2D-4BD0-9EBD-852F67FDD6B3Q46878240-37088682-C22C-458E-97B0-2A21CCFA4943Q53589109-F3C7D6F2-3965-4311-9337-B8650EF73480
P2860
Cardiovascular events in users of sildenafil: results from first phase of prescription event monitoring in England
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Cardiovascular events in users ...... on event monitoring in England
@ast
Cardiovascular events in users ...... on event monitoring in England
@en
Cardiovascular events in users ...... on event monitoring in England
@nl
type
label
Cardiovascular events in users ...... on event monitoring in England
@ast
Cardiovascular events in users ...... on event monitoring in England
@en
Cardiovascular events in users ...... on event monitoring in England
@nl
prefLabel
Cardiovascular events in users ...... on event monitoring in England
@ast
Cardiovascular events in users ...... on event monitoring in England
@en
Cardiovascular events in users ...... on event monitoring in England
@nl
P2093
P356
P1433
P1476
Cardiovascular events in users ...... on event monitoring in England
@en
P2093
P2860
P356
10.1136/BMJ.322.7287.651
P407
P577
2001-03-17T00:00:00Z